UA108494C2 - Застосування (rs)-s-цикропропіл-s-(4-{[4-{[(1r,2r)-2-гідрокси-1-метилпропіл]окси}-5-(трифторметил)піримідин-2-іл]аміно}феніл)сульфоксіміду для лікування пухлин - Google Patents
Застосування (rs)-s-цикропропіл-s-(4-{[4-{[(1r,2r)-2-гідрокси-1-метилпропіл]окси}-5-(трифторметил)піримідин-2-іл]аміно}феніл)сульфоксіміду для лікування пухлинInfo
- Publication number
- UA108494C2 UA108494C2 UAA201212233A UAA201212233A UA108494C2 UA 108494 C2 UA108494 C2 UA 108494C2 UA A201212233 A UAA201212233 A UA A201212233A UA A201212233 A UAA201212233 A UA A201212233A UA 108494 C2 UA108494 C2 UA 108494C2
- Authority
- UA
- Ukraine
- Prior art keywords
- sulfoximide
- methylpropyl
- pyrimidin
- tumors
- oxy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 abstract 1
- 125000005555 sulfoximide group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010014426A DE102010014426A1 (de) | 2010-04-01 | 2010-04-01 | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| PCT/EP2011/054733 WO2011120922A1 (de) | 2010-04-01 | 2011-03-28 | Verwendung neuer pan-cdk-inhibitoren zur behandlung von tumoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA108494C2 true UA108494C2 (uk) | 2015-05-12 |
Family
ID=43858236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201212233A UA108494C2 (uk) | 2010-04-01 | 2011-03-28 | Застосування (rs)-s-цикропропіл-s-(4-{[4-{[(1r,2r)-2-гідрокси-1-метилпропіл]окси}-5-(трифторметил)піримідин-2-іл]аміно}феніл)сульфоксіміду для лікування пухлин |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130210846A1 (OSRAM) |
| EP (1) | EP2552450A1 (OSRAM) |
| JP (1) | JP5816259B2 (OSRAM) |
| KR (1) | KR20130014678A (OSRAM) |
| CN (1) | CN102834100A (OSRAM) |
| AU (1) | AU2011234654B2 (OSRAM) |
| BR (1) | BR112012024422A2 (OSRAM) |
| CA (1) | CA2794996A1 (OSRAM) |
| CL (1) | CL2012002753A1 (OSRAM) |
| CR (1) | CR20120502A (OSRAM) |
| DE (1) | DE102010014426A1 (OSRAM) |
| DO (1) | DOP2012000260A (OSRAM) |
| EC (1) | ECSP12012198A (OSRAM) |
| MA (1) | MA34098B1 (OSRAM) |
| MX (1) | MX337722B (OSRAM) |
| NZ (1) | NZ602710A (OSRAM) |
| PH (1) | PH12012501945A1 (OSRAM) |
| SG (2) | SG183925A1 (OSRAM) |
| TN (1) | TN2012000469A1 (OSRAM) |
| UA (1) | UA108494C2 (OSRAM) |
| WO (1) | WO2011120922A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140135215A (ko) * | 2012-03-21 | 2014-11-25 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 특정한 종양의 치료를 위한 (rs)-s-시클로프로필-s-(4-｛[4-｛[(1r, 2r)-2-히드록시-1-메틸프로필]옥시｝-5-(트리플루오로메틸)피리미딘-2-일]아미노｝페닐)술폭시미드의 용도 |
| US20160045496A1 (en) * | 2013-03-07 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours |
| ES2734568T3 (es) * | 2013-03-13 | 2019-12-10 | Oncoceutics Inc | 7-Bencil-10-(2-metilbencil)-2,6,7,8,9,10-hexahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3H)-ona para su uso en el tratamiento de cáncer |
| WO2014173815A1 (en) * | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
| EP3010902A1 (en) * | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| WO2015071231A1 (de) * | 2013-11-14 | 2015-05-21 | Bayer Pharma Aktiengesellschaft | Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren |
| CN109283263B (zh) * | 2017-07-21 | 2019-06-25 | 南京正大天晴制药有限公司 | 用于雷替曲塞合成质量控制的检测分析方法 |
| CN109283279B (zh) * | 2017-07-21 | 2019-11-01 | 南京正大天晴制药有限公司 | 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法 |
| IL303237A (en) * | 2020-11-27 | 2023-07-01 | Anrui Biomedical Tech Guangzhou Co Ltd | Aminoheteroaryl kinase inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
| ES2253821T3 (es) | 1997-07-12 | 2006-06-01 | Cancer Research Technology Limited | Derivados de purina inhibidores de quinasa que depende de ciclina. |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| ES2270612T3 (es) | 1998-08-29 | 2007-04-01 | Astrazeneca Ab | Compuestos de pirimidina. |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| IL159120A0 (en) | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| EP1483260A1 (de) | 2002-03-11 | 2004-12-08 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
| DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| DE102006027156A1 (de) * | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
| EP1878726A1 (en) * | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same |
| EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
| US20090203709A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
| EP2179991A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2010
- 2010-04-01 DE DE102010014426A patent/DE102010014426A1/de not_active Withdrawn
-
2011
- 2011-03-28 NZ NZ602710A patent/NZ602710A/en not_active IP Right Cessation
- 2011-03-28 US US13/638,833 patent/US20130210846A1/en not_active Abandoned
- 2011-03-28 CN CN2011800166124A patent/CN102834100A/zh active Pending
- 2011-03-28 CA CA2794996A patent/CA2794996A1/en not_active Abandoned
- 2011-03-28 SG SG2012065819A patent/SG183925A1/en unknown
- 2011-03-28 SG SG10201502566SA patent/SG10201502566SA/en unknown
- 2011-03-28 BR BR112012024422A patent/BR112012024422A2/pt not_active IP Right Cessation
- 2011-03-28 WO PCT/EP2011/054733 patent/WO2011120922A1/de not_active Ceased
- 2011-03-28 AU AU2011234654A patent/AU2011234654B2/en not_active Ceased
- 2011-03-28 MX MX2012011427A patent/MX337722B/es active IP Right Grant
- 2011-03-28 JP JP2013501789A patent/JP5816259B2/ja not_active Expired - Fee Related
- 2011-03-28 MA MA35265A patent/MA34098B1/fr unknown
- 2011-03-28 EP EP11710224A patent/EP2552450A1/de not_active Withdrawn
- 2011-03-28 UA UAA201212233A patent/UA108494C2/uk unknown
- 2011-03-28 KR KR1020127025684A patent/KR20130014678A/ko not_active Ceased
- 2011-03-28 PH PH1/2012/501945A patent/PH12012501945A1/en unknown
-
2012
- 2012-09-27 TN TNP2012000469A patent/TN2012000469A1/en unknown
- 2012-10-01 EC ECSP12012198 patent/ECSP12012198A/es unknown
- 2012-10-01 CR CR20120502A patent/CR20120502A/es unknown
- 2012-10-01 CL CL2012002753A patent/CL2012002753A1/es unknown
- 2012-10-01 DO DO2012000260A patent/DOP2012000260A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP12012198A (es) | 2012-10-30 |
| MX337722B (es) | 2016-03-16 |
| AU2011234654A1 (en) | 2012-10-25 |
| TN2012000469A1 (en) | 2014-01-30 |
| AU2011234654B2 (en) | 2015-08-06 |
| PH12012501945A1 (en) | 2017-08-09 |
| EP2552450A1 (de) | 2013-02-06 |
| MX2012011427A (es) | 2013-03-05 |
| BR112012024422A2 (pt) | 2016-05-31 |
| DOP2012000260A (es) | 2013-03-31 |
| SG10201502566SA (en) | 2015-05-28 |
| MA34098B1 (fr) | 2013-03-05 |
| JP5816259B2 (ja) | 2015-11-18 |
| WO2011120922A1 (de) | 2011-10-06 |
| CN102834100A (zh) | 2012-12-19 |
| CL2012002753A1 (es) | 2013-01-18 |
| JP2013523680A (ja) | 2013-06-17 |
| DE102010014426A1 (de) | 2011-10-06 |
| NZ602710A (en) | 2014-05-30 |
| SG183925A1 (en) | 2012-10-30 |
| US20130210846A1 (en) | 2013-08-15 |
| CA2794996A1 (en) | 2011-10-06 |
| KR20130014678A (ko) | 2013-02-08 |
| CR20120502A (es) | 2012-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| UA108494C2 (uk) | Застосування (rs)-s-цикропропіл-s-(4-{[4-{[(1r,2r)-2-гідрокси-1-метилпропіл]окси}-5-(трифторметил)піримідин-2-іл]аміно}феніл)сульфоксіміду для лікування пухлин | |
| EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| IL235607A0 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| EA201492223A1 (ru) | Новые диазаспироциклоалканы и азаспироциклоалканы | |
| EA201390074A1 (ru) | 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения | |
| EA201290642A1 (ru) | Соединения и способы | |
| MA34091B1 (fr) | Anticorps anti-cd40 | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| UA113062C2 (xx) | Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону | |
| EA201891833A1 (ru) | Комбинация для лечения амиотрофического бокового склероза или родственных болезней | |
| MX384191B (es) | Molecula de union al antigeno especifico para el tejido objetivo. | |
| EA201201016A1 (ru) | Антидоты антикоагулянтов | |
| EA201390081A1 (ru) | Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение | |
| EA201300388A1 (ru) | Соединения замещенного бензамида | |
| EA201300610A1 (ru) | Хиназолинкарбоксамидазетидины | |
| EA201590552A1 (ru) | Аминохинолины в качестве ингибиторов киназы | |
| CL2013000797A1 (es) | Proceso de preparacion de (2r,3r)-3-{4-(s-(ciclo)alquil-sulfonimidoil)fenil}amino}-5-(trifluorometil)pirimidin-4-il}oxi}butan-2-2ol inhibidores; y los compuestos intermediarios considerados. | |
| EA201300946A1 (ru) | Асимметричные мочевины и их медицинское применение | |
| EA201400339A1 (ru) | Новые имидазоламины в качестве модуляторов киназной активности | |
| MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| EA201270256A1 (ru) | Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида | |
| LT2782602T (lt) | Nukleotidas dims0-150, skirtas lėtinio aktyvaus opinio kolito gydymui | |
| EA201301090A1 (ru) | Антидоты антикоагулянтов |